Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 992-999

  Mazières, Julien ^a   Rouvière, Damien ^a   D Milia, Julie ^a   Filleron, Thomas ^b   Zalcman, Gérard ^b   Biondani, Pamela ^c   Besse, Benjamin ^c   Barlesi, Fabrice ^d   Léna, Hervé ^e   Monnet, Isabelle ^f   Thiberville, Luc ^g   Pecuchet, Nicolas ^h,i   Crinò, Lucio ^j   Cappuzzo, Federico ^k   Dingemans, Anne Marie C ^l   Smit Sacha I Rothschild, Egbert F ^m,n   Spirig, Christian ^o   Diebold, Joachim ^p   Gautschi, Oliver ^p   Dziadziuszko, Rafal ^q   Wolf, Jurgen ^r   Thomas, Roman K ^r   Leenders, Frauke ^s   Heuckmann, Johannes M ^t   more..

^a SERVICE DE PNEUMOLOGIE   (France)

^b Institut Universitaire du Cancer   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ INSTITUT CURIE   (France)

^j Azienda Ospedaliera   (Italy)

^k ISTITUTO TOSCANO TUMORI   (Italy)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o Klinik St Anna   (Switzerland)

^p LUZERNER KANTONSSPITAL   (Switzerland)

^q MEDICAL UNIVERSITY OF GDANSK   (Poland)

^r UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^s UNIVERSITY OF COLOGNE   (Germany)

^t NEO New Oncology GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PEMETREXED; PLATINUM; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EUROPE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; LIVER TOXICITY; LUNG ADENOCARCINOMA; MALE; MULTICENTER STUDY; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; ROS1 GENE; TREATMENT RESPONSE; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; OFF-LABEL USE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RETROSPECTIVE STUDIES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84927139647     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.3302     Document Type: Article

References (48)

1. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180, 2011
2. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
3. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
4. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
5. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
6. Jänne PA, Shaw AT, Pereira JR, et al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38-47, 2013
7. Gandhi L, Bahleda R, Tolaney SM, et al: Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68-75, 2014
8. Planchard D, Mazieres J, Riely GJ, et al: Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive nonsmall cell lung cancer (NSCLC) patients. J Clin Oncol 31, 2013 (suppl; abstr 8009)
9. Drilon A, Wang L, Hasanovic A, et al: Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630-635, 2013
10. Cappuzzo F, Bemis L, Varella-Garcia M: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354:2619-2621, 2006
11. Mazières J, Peters S, Lepage B, et al: Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997-2003, 2013
12. Gautschi O, Pauli C, Strobel K, et al: A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7:e23-e24, 2012
13. Gautschi O, Zander T, Keller FA, et al: A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8:e43-e44, 2013
14. Birchmeier C, O'Neill K, Riggs M, et al: Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci U S A 87:4799-4803, 1990
15. Birchmeier C, Sharma S, Wigler M: Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 84: 9270-9274, 1987
16. Charest A, Lane K, McMahon K, et al: Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37:58-71, 2003
17. Charest A, Wilker EW, McLaughlin ME, et al: ROS fusion tyrosine kinase activates a SH2 domaincontaining phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66:7473-7481, 2006
18. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007
19. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
20. Davies KD, Le AT, Theodoro MF, et al: Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579, 2012
21. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
22. Davies KD, Doebele RC: Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040-4045, 2013
23. Pan Y, Zhang Y, Li Y, et al: ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion patternspecific clinicopathologic, histologic and cytologic features. Lung Cancer 84:121-126, 2014
24. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
25. Mok T, Kim D-W, Wu Y-L, et al: First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): Results of a phase III study (PROFILE 1014). J Clin Oncol 32, 2014 (suppl 5s; abstr 8002)
26. Camidge DR, Ou S-HI, Shapiro G, et al: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32, 2014 (suppl 15; abstr 8001)
27. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, et al: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7:1086-1090, 2012
28. Shaw AT, Ou SH, Bang YJ, et al: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-1971, 2014
29. Bos M, Gardizi M, Schildhaus HU, et al: Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 81:142-143, 2013
30. Dziadziuszko K, Szurowska E, Pienkowska J, et al: Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: A case report. J Thorac Oncol 9:e34-e36, 2014
31. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
32. Fernandez-Cuesta L, Plenker D, Osada H, et al: CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4:415-422, 2014
33. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007
34. Mescam-Mancini L, LantuéjoulS, Moro-Sibilot D, et al: On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 83:168-173, 2014
35. Riess JW, Padda SK, Bangs CD, et al: A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer 14:592-595, 2013
36. Warth A, Muley T, Dienemann H, et al: ROS1 expression and translocations in non-small-cell lung cancer: Clinicopathological analysis of 1478 cases. Histopathology 65:187-194, 2014
37. Kim MH, Shim HS, Kang DR, et al: Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Lung Cancer 83:389-395, 2014
38. Arai Y, Totoki Y, Takahashi H, et al: Mouse model for ROS1-rearranged lung cancer. PLoS One 8:e56010, 2013
39. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
40. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002
41. Go H, Kim DW, Kim D, et al: Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 8:1445-1450, 2013
42. Kim HR, Lim SM, Kim HJ, et al: The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24:2364-2370, 2013
43. Cha YJ, Lee JS, Kim HR, et al: Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One 9:e103333, 2014
44. Gerlinger M, Norton L, Swanton C: Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 369:1172-1173, 2013
45. Awad MM, Katayama R, McTigue M, et al: Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368:2395-2401, 2013
46. Ou SH, Soo RA, Kubo A, et al: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-, NTRK1-) non-small cell lung cancer globally? Front Oncol 4:58, 2014
47. Mok TS: A target or a demi-target. Clin Lung Cancer 11:147-148, 2010
48. Johnson DH, Schiller JH, Bunn PA Jr: Recent clinical advances in lung cancer management. J Clin Oncol 32:973-982, 2014